Prognostic role of K-Ras mutations in non-small cell lung cancer: Still an issue for open debate

Lung Cancer

Volumn 53, Issue 3, 2006, Pages 393-395

  Neri, Monica ^a   Cesario, Alfredo ^b,c   Granone, Pierluigi ^b   Dominioni, Lorenzo ^d   Puntoni, Riccardo ^a   D'Angelillo, Rolando Maria ^e   Russo, Patrizia ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

K Ras; Lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; OXALIPLATIN; PLATINUM DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CELL STRAIN 3T3; CELL VIABILITY; CYTOTOXICITY; DNA ADDUCT; DNA REPAIR; DRUG SENSITIVITY; GENE ACTIVATION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; ONCOGENE H RAS; ONCOGENE K RAS; PLASMA; PRIORITY JOURNAL; PROGNOSIS; SERUM; TREATMENT OUTCOME; TUMOR BIOPSY; WILD TYPE;

EID: 33746866363     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.06.009     Document Type: Letter

References (10)

1. Camps C., Sirera R., Bremnes R., et al. Is there a prognostic role of k-ras point mutations in the serum of patients with advanced non small cell lung cancer?. Lung Cancer 50 (2005) 339-346
2. Mascaux C., Iannino N., Martin B., et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92 (2005) 131-139
3. Youn C.K., Kim M.H., Cho H.J., et al. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res 64 (2004) 4849-4857
4. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24 (1998) 331-344
5. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 (2001) 42304-42984
6. Lord R.V., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
7. Sklar M.D. Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transfected by ras oncogene. Cancer Res 48 (1988) 793-797
8. Vekris A., Meynard D., Haaz M.C., et al. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res. 64 (2004) 356-362
9. Trombino S., Neri M., Puntoni R., et al. Mutations in K-ras codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancer. Clin Chem 51 (2005) 1313-1314
10. Kopreski M.S., Benko F.A., Borys D.J., et al. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst 92 11 (2000) 918-923